Results 81 to 90 of about 2,590,210 (272)

Real‐world drivers of treatment choices in synchronous metastatic renal cell carcinoma

BJUI Compass, Volume 7, Issue 1, January 2026.
Abstract Objectives This study aimed to identify clinical and socioeconomic factors associated with treatment selection and survival in patients diagnosed with synchronous metastatic renal cell carcinoma (mRCC). Patients and Methods The Renal Cell Cancer Database Sweden (RCCBaSe2.0), linking the National Swedish Kidney Cancer Register with other ...
Tarik Almdalal, Maja Fahlén, Ulrika Harmenberg, Börje Ljungberg, Magnus Lindskog   +4 more
wiley   +1 more source

The impact of radiotherapy on the prognosis of metastatic clear cell renal cell carcinoma after surgery

Scientific Reports
Clear cell renal cell carcinoma, one of the most common types of renal cell carcinoma, has been increasing in incidence year by year. This study aims to investigate the impact of radiotherapy on the prognosis of patients with metastatic clear cell renal ...
Xuwen Li, Zhongyu Tan, Yihao Zhu, Yabo Zhai, Can Chen, Dong Wang, Mingshuai Wang, Nianzeng Xing, Feiya Yang, Xiongjun Ye   +9 more
doaj   +1 more source

Retroperitoneal Dedifferentiated Liposarcoma With Penetrating Abscess Formation Secondary to Ileal Invasion: A Case Report

Clinical Case Reports, Volume 14, Issue 1, January 2026.
ABSTRACT Liposarcoma is a relatively common malignant soft tissue tumor in adults. Dedifferentiated liposarcoma (DLS) is a particularly invasive subtype characterized by high recurrence rates and a poor prognosis. We describe a case of a retroperitoneal liposarcoma with poor differentiation that presented with peritonitis accompanied by ileal ...
Kenichiro Yambe, Kei Nakagawa, Kuniharu Yamamoto, Hiroto Sakurai, Kazuhiro Takami, Noriko Kondo, Chikashi Shibata, Yu Katayose   +7 more
wiley   +1 more source

Impact of Antihypertensive Treatment on Outcomes of Adjuvant Bevacizumab for Ovarian Cancer (IATRO), Results from a Nationwide Emulated Clinical Trial

Clinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 198-207, January 2026.
Antiangiogenic therapy with bevacizumab improves outcomes in ovarian cancer but induces hypertension, leading to major adverse cardiovascular events (MACE). While calcium channel blockers (CCBs) and angiotensin‐converting enzyme inhibitors (ACEi) are recommended for managing bevacizumab‐associated hypertension, their impacts on cancer progression and ...
Floriane Jochum, Élise Dumas, Joe‐Elie Salem, Stéphane Ederhy, Anne‐Sophie Hamy, Lise Lecointre, Enora Laas, Fabien Reyal, Fabrice Lecuru, Cherif Akladios, Paul Gougis   +10 more
wiley   +1 more source

Cholecystectomy at the time of open cytoreductive surgery for ovarian cancer

Gynecologic Oncology Reports
Introduction: We sought to demonstrate a method of performing open cholecystectomy at the time of cytoreductive surgery for ovarian cancer. Case/Methods: In this surgical film, we present the case of a 78-year-old woman with metastatic high-grade serous ...
Lindsey Finch, Danyal Ahsan Muhammad, Dennis S. Chi   +2 more
doaj   +1 more source

CYTOREDUCTIVE OPERATIONS IN TREATMENT OF THE PATIENTS OF ELDERLY AND SENILE AGE WITH DISSEMINATED FORMS OF COLORECTAL CANCER

Вестник хирургии имени И.И. Грекова, 2016
Late diagnostics of colon cancer along with high specific weight of the patients of elder age groups indicated the urgency of study of application of cytoreductive surgery in elderly and senile patients of with colorectal cancer. A comparative assessment
N. A. Maistrenko, A. A. Khvatov, A. A. Sazonov   +2 more
doaj   +1 more source

14/#650 The value of PET/CT for cytoreductive surgery selection in recurrent ovarian carcinoma [PDF]

, 2022
Rafael Leite Nunes, Flávio Teixeira, Bruna Goncalves, Carlos Chaves Faloppa, Lillian Yuri Kumagai, Henrique Mantoan, Levon Badiglian‐Filho, Andréa Carmen Guimarães, Alexandre Da Costa, Glauco Baiocchi   +9 more
openalex   +1 more source

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.

The Lancet Oncology, 2021
F. Quénet, D. Elias, L. Roca, D. Goéré, L. Ghouti, M. Pocard, O. Facy, C. Arvieux, G. Lorimier, D. Pezet, F. Marchal, V. Loi, P. Meeus, B. Juzyna, H. De forges, J. Paineau, O. Glehen   +16 more
semanticscholar   +1 more source

Revisiting intraperitoneal chemotherapy for advanced high‐grade serous ovarian cancer

International Journal of Gynecology &Obstetrics, Volume 172, Issue 1, Page 215-222, January 2026.
Abstract Objective To compare overall survival (OS) in patients with high‐grade serous ovarian cancer (HGSOC) treated with intraperitoneal (IP) chemotherapy versus intravenous (IV) chemotherapy. Methods A retrospective study of Stage III HGSOC with optimal primary cytoreduction during 2007–2019, followed by adjuvant IP or IV chemotherapy.
Joshua S Cheruvathur, Gabriel Levin, Reitan Ribeiro, Florentin Racovitan, Joanne Power, Xing Zeng, John Sampalis, Lucy Gilbert   +7 more
wiley   +1 more source

The Results of Cytoreductive Operations in Patients with Colorectal Cancer with Simultaneous Liver Polymetastases

Наука и инновации в медицине, 2018
Aim - to improve the long-term results of cytoreductive treatment of patients with simultaneous multiple bilobar liver metastases of colorectal cancer by the use of RFTA. Materials and methods.
SV V Kozlov, OI I Kaganov, AE E Orlov, AM M Kozlov   +3 more
doaj   +1 more source